Conatus Pharmaceuticals (CNAT) PT Lowered to $14 at H.C. Wainwright

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. SPY
9. XYZ
10. FISV

Go back to Conatus Pharmaceuticals (CNAT) PT Lowered to $14 at H.C. Wainwright

Conatus Announces Results from ENCORE-PH Phase 2b Clinical Trial in NASH Cirrhosis

December 5, 2018 7:30 AM EST

- Clinically Meaningful Improvements in Portal Hypertension in High Risk Compensated Cirrhosis Patients -

- Conference Call and Webcast Presentation at 8:30 a.m. ET Today -

SAN DIEGO, Dec. 05, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq: CNAT) today announced top-line results from the companys Phase 2b ENCORE-PH clinical trial showing clinically meaningful treatment effects in compensated NASH cirrhosis patients at high risk of decompensation. The trials primary endpoint was change in mean hepatic venous pressure gradient (HVPG) from... More